nach oben

Erschienen in:

01.10.2011

Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome

verfasst von: Clothilde Martel, Guillaume Gondran, David Launay, Fabrice Lalloué, Sylvain Palat, Marc Lambert, Kim Ly, Veronique Loustaud-Ratti, Holly Bezanahary, Eric Hachulla, Marie Odile Jauberteau, Elisabeth Vidal, Pierre Yves Hatron, Anne Laure Fauchais

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this paper was to study the evolution of primary Sjögren’s syndrome (pSS) immunological profile, its impact on pSS activity and long-term evolution in a bicentric cohort of French patients with pSS (n = 445, mean age 53.6 ± 14 years, mean follow-up 76.1 ± 51 months).

Methods

This is a retrospective cohort study.

Results

Two hundred twelve patients were Sjögren’s syndrome A (SSA) positive, and 131 were both SSA and Sjögren’s syndrome B (SSB) positive. Sixty-eight patients (15%) had cryoglobulinemia. Active systemic profile (i.e., hypergammaglobulinemia, rheumatoid factor (RF), and anti-Sjögren’s syndrome A (anti-SSA), anti-Sjögren’s syndrome B (anti-SSB) positivity), associated with multisystemic involvement, leads to an increased utilization of corticosteroid and hydroxychloroquine. Multivariate analysis pointed out independent statistical association between hypergammaglobulinemia, anti-SSA, anti-SSB, and RF. Cryoglobulinemia is associated with multi-systemic involvement, lymphoma, and pSS-related death.

Conclusion

The subset of patients with active immunological profile is characterized by systemic complications leading to immunosuppressive drug utilization and polyclonal B-cell activation profile.

Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12(5):391–8.PubMedCrossRef

Alexander E, Arnett F, Provost T. Sjögren’s syndrome: association of anti-SSa antibodies with vasculitis, immunologic abnormalities and serologic hyperactivity. Ann Med Int. 1983;98:155–9.

Pease CT, Shattles W, Charles PJ, Venables PJ, Maini RN. Clinical, serological, and HLA phenotype subsets in Sjögren’s syndrome. Clin Exp Rheumatol. 1989;7(2):185–90.PubMed

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. European study group on classification criteria for Sjögren’s syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.PubMedCrossRef

Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210–9.CrossRef

Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46(3):741–7.PubMedCrossRef

Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, et al. Articular manifestations in primary Sjögren syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford). 2010;49(6):1164–72.CrossRef

Van Bijsterveld O. Diagnosis and differential diagnosis of keratoconjunctivitis sicca associated with tear gland degeneration. Clin Exp Rheumatol. 1990;8(5):3–6.PubMed

Schall G, Andferson L, Wolf R, Herdt J, Tarpley T, Cummings N, et al. Xerostomia in Sjögren’s syndrome. Evaluation by sequential salivary scintigraphy. JAMA. 1971;216:2109–16.PubMedCrossRef

10.

Chisholm D. Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol. 1968;21:656–60.PubMedCrossRef

11.

Asmussen K, Andersen V, Bendixen G, Schiodt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996;239(6):475–82.PubMedCrossRef

12.

Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–93.CrossRef

13.

Muller K, Oxholm P, Mier-Madsen M, Wiik A. Circulating IgA- and IgM-rheumatoid factors in patients with primary Sjögren syndrome. Correlation to extraglandular manifestations. Scand J Rheumatol. 1989;18(1):29–31.PubMedCrossRef

14.

Fauchais A, Lambert M, Dubucquoi S, Hachulla E, Pasturel U, Queyrel V, et al. Inaugural Raynaud’s phenomemon is associated with a multisystemic involvement during follow up in primary Sjögren syndrome—A report of 162 patients. Int J Angiology. 2004;13(2):1061–711.

15.

Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270–80.CrossRef

16.

Ramos M, Cervera R, Garcia-Carrasco M, Miret C, Munoz FJ, Espinosa G, et al. Primary Sjögren’s syndrome: clinical and immunologic study of 80 patients. Med Clin (Barc). 1997;108(17):652–7.

17.

Ramos-Casals M, Font J, Garcia-Carrasco M, Brito MP, Rosas J, Calvo-Alen J, et al. Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81(4):281–92.CrossRef

18.

Ramos-Casals M, Anaya JM, Garcia-Carrasco M, Rosas J, Bove A, Claver G, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004;83(2):96–106.CrossRef

19.

Leone J, Pennaforte JL, Hamon R, Cleenewerck N, Vallerand H, Detree F, et al. Pulmonary manifestations of primary Gougerot-Sjögren syndrome. Apropos of 8 cases in a series of 35 patients. Rev Med Interne. 1996;17(4):291–9.PubMedCrossRef

20.

Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren’s syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol. 1995;24(6):342–5.PubMedCrossRef

21.

Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 1996;39(5):767–72.PubMedCrossRef

22.

Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796–803.PubMedCrossRef

23.

Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren’s syndrome patients. Clin Rev Allergy Immunol. 2007;32(3):265–74.PubMedCrossRef

24.

Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359–62.CrossRef

25.

Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjögren’s syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol. 2000;123(1):46–57.PubMedCrossRef

26.

Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome. Ann Rheum Dis. 2005;64(7):1050–5.PubMedCrossRef

27.

Kelly CA, Foster H, Pal B, Gardiner P, Malcolm AJ, Charles P, et al. Primary Sjögren’s syndrome in north east England–a longitudinal study. Br J Rheumatol. 1991;30(6):437–42.PubMedCrossRef

28.

Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford). 1999;38(3):245–53.CrossRef

29.

Cho CS, Park SH, Min JK, Lee SH, Kim HY. Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren’s syndrome. Korean J Intern Med. 1997;12(2):176–81.PubMed

30.

Ichigawa Y, Takada M, Shimizu H, Uchiyama M, Motiushi J, Morita K. Clinical and immunological features of 106 patients with primary Sjögren’s syndrome: comparison of patients with and without other specific autoimmune disease or anti-SSa antibodies. Jap J of Rheum. 1993;4(3):153–64.

31.

Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren’s syndrome. Scand J Rheumatol. 1999;28(4):227–32.PubMedCrossRef

32.

Ramos-Casals M, Cervera R, Font J, Garcia-Carrasco M, Espinosa G, Reino S, et al. Young onset of primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus. 1998;7(3):202–6.PubMedCrossRef

Titel: Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome
verfasst von: Clothilde Martel
Guillaume Gondran
David Launay
Fabrice Lalloué
Sylvain Palat
Marc Lambert
Kim Ly
Veronique Loustaud-Ratti
Holly Bezanahary
Eric Hachulla
Marie Odile Jauberteau
Elisabeth Vidal
Pierre Yves Hatron
Anne Laure Fauchais
Publikationsdatum: 01.10.2011
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 5/2011
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-011-9553-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome

Abstract

Background

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Individual Antibody and T Cell Responses to Vaccination and Infection with the 2009 Pandemic Swine-Origin H1N1 Influenza Virus

Endogenously Activated Interleukin-4 Differentiates Disease Progressors and Non-Progressors in Tuberculosis Susceptible Families: A 2-Year Biomarkers Follow-Up Study

Disseminated BCG Infection Mimicking Metastatic Nasopharyngeal Carcinoma in an Immunodeficient Child with a Novel Hypomorphic NEMO Mutation

The Possible Roles of OPN-Regulated CEACAM1 Expression in Promoting the Survival of Activated T Cells and the Apoptosis of Oral Keratinocytes in Oral Lichen Planus Patients

Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Defective T Cell Chemotaxis to Sphingosine 1-Phosphate and Chemokine CCL21 in Idiopathic T Lymphocytopenia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin